Sartorius AGSARTF -1.83%85 EBITDA Margin % is 31.21% as of Mar. 2026, which is 22% above its 10-year median of 25.58. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sartorius AG ranks better than 86.03% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sartorius AG's EBITDA for the
three
months ended in Mar. 2026 was $324 Mil. Sartorius AG's Revenue for the
three
months ended in Mar. 2026 was $1,039 Mil. Therefore, Sartorius AG's EBITDA margin for the quarter that ended in Mar. 2026 was 31.21%.
Sartorius AG (OTCPK:SARTF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sartorius AG EBITDA Margin % Related Terms
Sartorius AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EBITDA Margin % of 31.21% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sartorius AG and its competitors. This is 22% above median its historical median of 25.58. Over the past decade, Sartorius AG's EBITDA Margin % has ranged from 22.25 to 36.03. According to the industry distribution chart, Sartorius AG ranks #114 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Sartorius AG's EBITDA Margin % too high?
Sartorius AG's current EBITDA Margin % of 31.21% is 22% above median its 10-year median of 25.58. Over the past 10 years, this metric has ranged from a low of 22.25 to a high of 36.03. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Sartorius AG's value of 31.21% is 317.5% above this industry median. Based on the distribution chart, Sartorius AG ranks #114 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #114 out of 816 companies for EBITDA Margin %. This places Sartorius AG in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Sartorius AG's value of 31.21% is 317.5% above this benchmark. Historically, Sartorius AG's own EBITDA Margin % has ranged from 22.25 to 36.03 over the past decade. While the company's 10-year median is 25.58 vs. the industry median of 7.48, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EBITDA Margin % of 31.21% is 317.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EBITDA Margin % is 31.21%, which is 22% above median its own 10-year median of 25.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current EBITDA Margin % is 31.21%, which is 22% above median its 10-year median of 25.58 and 317.5% above the Medical Devices & Instruments industry median of 7.48. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EBITDA Margin % is 31.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
EBITDA Margin %: 31.21% (22% above median its 10-year median of 25.58)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
Industry Position: 317.5% above the Medical Devices & Instruments median (#114 of 816)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
